Valerion Therapeutics, LLC

About Valerion Therapeutics, LLC

Valerion Therapeutics (www.valerion.com) is a biotechnology company focused on developing therapies for orphan genetic diseases utilizing a proprietary antibody-mediated delivery platform to target specific tissues.
This platform is capable of enhanced intracellular delivery of a variety of active therapeutic molecules via a well-known and broadly studied transport mechanism that is present in muscles and neurons. Pipeline candidates include therapies aimed at addressing orphan genetic disorders with limited or no current therapies. Valerion Therapeutics is part of the Alopexx Enterprises portfolio of companies (www.alopexx.com).
YEAR FOUNDED:
2007
LEADERSHIP:
CEO: Deborah Ramsdell
CSO: Dustin Armstrong
CMO: Hal Landy
CLINICAL TRIAL:
Please click here for clinical trial information.